0QLQ.LSE

Ypsomed Holding AG

0QLQ.LSE, UK

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

https://www.ypsomed.com

Stock Price

£0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

1.79

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.66

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

High

17.23 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

11.51 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

1.12 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.50

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Ypsomed Holding AG

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

—

Latest Release

Date

—

EPS Actual

—

EPS Estimate

—

EPS Difference

—

Surprise Percent

undefined%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(10)
GARP
Strong GARP(9.5)
Growth
High Growth(7.5)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(9)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

£ 0

Cost Of Revenue

£ 0

Gross Profit

£ 0

Operating Expenses

£ 0

Operating Income

£ 0

Interest Expense

£ 0

Pretax Income

£ 0

Net Income

£ 0

Income Tax Expense

£ 0

EBITDA

£ 0

Total Other Income Expense Net

£ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

£ 0

Short Term Investments

£ 0

Receivables

£ 0

Inventories

£ 0

Total Current Assets

£ 0

Property Plant Equipment

£ 0

Total Assets

£ 0

Payables

£ 0

Short Term Debt

£ 0

Long Term Debt

£ 0

Total Liabilities

£ 0

Equity

£ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

£ 0

Depreciation

£ 0

Change In Working Capital

£ 0

Cash From Operations

£ 0

Capital Expenditures

£ 0

Cash From Investing

£ 0

Cash From Financing

£ 0

Net Change In Cash

£ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.